These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9000569)

  • 1. Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug.
    Miners JO; Valente L; Lillywhite KJ; Mackenzie PI; Burchell B; Baguley BC; Kestell P
    Cancer Res; 1997 Jan; 57(2):284-9. PubMed ID: 9000569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhou S; Kestell P; Tingle MD; Paxton JW
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid.
    Zhou S; Paxton JW; Tingle MD; Kestell P
    Drug Metab Dispos; 2000 Dec; 28(12):1449-56. PubMed ID: 11095582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.
    Zhou S; Chin R; Kestell P; Tingle MD; Paxton JW
    Br J Clin Pharmacol; 2001 Aug; 52(2):129-36. PubMed ID: 11488768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
    Zhou S; Paxton JW; Kestell P; Tingle MD; Ching LM
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):319-26. PubMed ID: 11345648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species.
    Zhou S; Kestell P; Paxton JW
    J Pharm Pharmacol; 2002 Jul; 54(7):997-1003. PubMed ID: 12162720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
    Zhou S; Kestell P; Baguley BC; Paxton JW
    Biochem Pharmacol; 2003 Jun; 65(11):1853-65. PubMed ID: 12781337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo.
    Zhou SF; Tingle MD; Kestell P; Paxton JW
    Xenobiotica; 2002 Feb; 32(2):87-107. PubMed ID: 11868972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.
    Zhou S; Kestell P; Paxton JW
    Drug Metab Rev; 2002 Nov; 34(4):751-90. PubMed ID: 12487149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
    Zhou S; Kestell P; Baguley BC; Paxton JW
    Biochem Pharmacol; 2003 Jan; 65(1):109-20. PubMed ID: 12473385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice.
    Zhou S; Kestell P; Paxton JW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Sep; 776(2):231-6. PubMed ID: 12138005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial.
    Jameson MB; Baguley BC; Kestell P; Zhao L; Paxton JW; Thompson PI; Waller S;
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):681-7. PubMed ID: 17021822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines.
    Woon ST; Baguley BC; Palmer BD; Fraser JD; Ching LM
    Oncol Res; 2002; 13(2):95-101. PubMed ID: 12392157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells.
    Zhou S; Feng X; Kestell P; Paxton JW; Baguley BC; Chan E
    Eur J Pharm Sci; 2005 Apr; 24(5):513-24. PubMed ID: 15784341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide.
    Kestell P; Zhao L; Baguley BC; Palmer BD; Muller G; Paxton JW; Ching LM
    Cancer Chemother Pharmacol; 2000; 46(2):135-41. PubMed ID: 10972483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver.
    Webster LK; Ellis AG; Kestell P; Rewcastle GW
    Drug Metab Dispos; 1995 Mar; 23(3):363-8. PubMed ID: 7628302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
    Zhou S; Kestell P; Baguley BC; Paxton JW
    Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of anticancer drugs on the glucuronidation of 3'-azido-3'-deoxythymidine in human liver microsomes.
    Rajaonarison JF; Lacarelle B; Catalin J; Durand A; Cano JP
    Drug Metab Dispos; 1993; 21(5):823-9. PubMed ID: 7902243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans.
    Raungrut P; Uchaipichat V; Elliot DJ; Janchawee B; Somogyi AA; Miners JO
    J Pharmacol Exp Ther; 2010 Aug; 334(2):609-18. PubMed ID: 20484152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
    Zhou S; Kestell P; Tingle MD; Ching LM; Paxton JW
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):541-4. PubMed ID: 11459209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.